Hutchmed (China) Limited 2022 Annual Report and Notice of AGM HCM +3.92%
UK Regulatory (RNS & others) - Today @ 09:30
Hong Kong, Shanghai, & Florham Park, NJ - Tuesday, April 11, 2023: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that its 2022 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy ("AGM Materials") will be posted to shareholders on April 12, 2023 who have elected to receive the AGM Materials in printed form. The documents can also be accessed from the HUTCHMED website (www.hutch-med.com). |
This is a bit more like it! Decent RNS. |
Is it because I is Chinese? |
In my inbox today from Trinity Delta:
HUTCHMED’s transition into a sustainably profitable global biopharma continues to gather momentum, as evidenced in FY22 results, with growing commercial traction in China and pipeline progress with key assets. Global ambitions are now being addressed with partners. Positive fruquintinib FRESCO-2 data, completion of US FDA rolling filing, and execution of a global ex-China commercial and development deal with Takeda brings first launch of a HUTCHMED product outside of China even closer. The $400m Takeda upfront will boost the balance sheet and the prospect of further downstream economics enables HUTCHMED to focus on progressing its priority late-stage assets which, with plans to secure further strategic partnerships, should drive near-term value. Our HUTCHMED valuation is US$5.5bn (US$32.01 per ADS), £4.6bn and HK$43.2bn (534p or HK$49.94 per share).
Guess the market doesn't give a &%@! what TD think! |
Yes hard to fathom the price action here. Things seem to be shaping up nicely yet we go lower. |
In the field of investment,Hutchmed can be characterised as a booby trap. |
I had a meeting with Cheng a few years back - he has no concept of Investors . Had no idea of the route to profitability or why it was needed.
Old style Chinese company man . Really needs to go.... |
Buying opp methinks. |
Poor reaction to sale of stock by Johnny Cheng.Certainly takes the gloss of the Takeda RNS.Shouldn't Johnny be adding to his holding!That said,he's recently been awarded a shed load of options.Dear old Hutchmed is incompetent when it comes to nurturing its investor base. |
the fact they have a clearly executable and realistic path to profitability must surely please investors. The market will catch up but as you say the political environment is holding it back and the Taiwan situation may be a drag for some time. |
Story still intact and HCM continues to deliver.
Enough cash to get to +ve free cash flow without needing to go to market.
Realistic route to market strategy .
Only the political environment holding it back now….
Cheap as chips at this price. |
agreed steeple, great set of results and forecast to become profitable by 2025 which is way ahead of previous forecasts before the Takeda deal |
The update reads well.So much promise in the pipeline as confirmed by the tie ups with Takeda.Hopefully,the stock can resume its recovery. |
Stock testing 50 day moving average.Hopefully will provide support,if not,could fall back further. |
Disappointing retrace below 300p now. Would hope for more stability and steady progress upwards after the Takeda news, BUT, this is HCM! The wait continues for any meaningful action northwards! |
Good to see the faith that Takeda have in fruquintinib.
That’s because the TYK2 inhibitor for psoriasis Takeda is getting from Nimbus, along with the Hutchmed fruquintinib commercialization outside of China, are just two of what it reports are 10 late-stage development programs of promising candidates. |
As long as we stay above 300p for a while we should be okay. Not as fast as a certain balloon you may have been referring to! Was looking at the latest presentation and there is still so much to look forward to with HCM. The Takeda link looks very exciting too and the lady from Takeda on the conference call on the day of the RNS was very good IMO. Better than our CEO who is not quite as smooth as our former CEO, but can't have everything. |
Price coming back to earth like a deflating balloon :) |
HK currently trading up around 7% at over $20US equivalent which if matched in London implies around 325p.Maybe time for the London based MMs to widen that spread and keep a low profile until the Nasdaq opens :) |
Goldmans regards Takeda news as ‘significant’.Elsewhere,news has triggered broker upgrades. |
Royalty % likely to vary by market/region and also by volume……in the past HCM has agreed royalty deals said to be in the teens….AZN/Savo, Lilly/Fruquintinib and the in license deal now with IPSEN…and the Inmagene deal too.
So i expect 12-20%…to a certain extent it also reflects the up front payment…an increased investment should be rewarded with greater sales retention….we will need to see how the market feels about $400m now plus add ons (presumably for US,EU and JPN approval and other indications) and the manufacture / royalty income…..interestingly the deal suggests that Takeda will be able to manufacture which may also free up capacity in the new factory if needed in a few years time. |
No mention of royalties % in press release.I guess it'll be revealed at presentation timed for 1-30pm UK time. |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
